MedDataX Logo

DBT and Escitalopram in Borderline Personality Disorder

NCT ID: NCT00255554

Last Updated: 2005-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Borderline Personality Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Borderline Personality Disorder BPD Dialectical Behavior Therapy DBT Escitalopram Lexapro

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dialectical Behavioral Therapy

Intervention Type BEHAVIORAL

Escitalopram

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bronx VA Medical Center

FED

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marianne Goodman, MD

Role: PRINCIPAL_INVESTIGATOR

Bronx VA Medical Center/Mount Sinai School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bronx VA Medical Center

The Bronx, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emily Hart

Role: CONTACT

Phone: 212-241-0441

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Stoffers-Winterling JM, Storebo OJ, Pereira Ribeiro J, Kongerslev MT, Vollm BA, Mattivi JT, Faltinsen E, Todorovac A, Jorgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2.

Reference Type DERIVED
PMID: 36375174 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3277-03-0027

Identifier Type: -

Identifier Source: org_study_id